Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Cancer Vaccine Maker Therion Is Up For Sale After Disappointing Phase III Results

This article was originally published in The Pink Sheet Daily

Executive Summary

Therion no longer plans to submit a BLA for its PANVAC-VF pancreatic cancer treatment.

You may also be interested in...



Bavarian Nordic To Take Prostvac Therapeutic Prostate Cancer Vaccine Into Phase III

Danish firm won license for the therapy, once held by defunct Therion, in CRADA with NCI.

Bavarian Nordic To Take Prostvac Therapeutic Prostate Cancer Vaccine Into Phase III

Danish firm won license for the therapy, once held by defunct Therion, in CRADA with NCI.

Bavarian Nordic To Take Prostvac Prostate Cancer Vaccine Into Phase III

Bavarian Nordic's attempt to reduce the risk associated with developing a cancer vaccine includes licensing a vetted therapy from the National Cancer Institute and developing it with the institute under a Cooperative Research and Development Agreement.

Related Content

Topics

UsernamePublicRestriction

Register

LL005491

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel